Olatz Arrizabalaga
Overview
Explore the profile of Olatz Arrizabalaga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
San Torcuato M, Bautista-Puig N, Arrizabalaga O, Mendez E
J Med Internet Res
. 2022 Oct;
24(10):e40011.
PMID: 36190742
Background: The COVID-19 outbreak highlighted the importance of rapid access to research. Objective: The aim of this study was to investigate research communication related to COVID-19, the level of openness...
2.
Arrizabalaga O, Otaegui D, Vergara I, Arrizabalaga J, Mendez E
F1000Res
. 2020 Aug;
9:649.
PMID: 32850121
The COVID-19 outbreak has made funders, researchers and publishers agree to have research publications, as well as other research outputs, such as data, become openly available. In this extraordinary research...
3.
Moreno-Cugnon L, Arrizabalaga O, Llarena I, Matheu A
Aging (Albany NY)
. 2020 Apr;
12(7):6030-6036.
PMID: 32243258
Age-progressive neural stem cell (NSC) dysfunction leads to impaired neurogenesis, cognitive decline and the onset of age-related neurodegenerative pathologies. p38MAPK signalling pathway limits stem cell activity during aging in several...
4.
Moreno-Cugnon L, Revuelta M, Arrizabalaga O, Colie S, Moreno-Valladares M, Jimenez-Blasco D, et al.
Aging Cell
. 2019 Sep;
18(6):e13044.
PMID: 31560167
Neuronal activity regulates cognition and neural stem cell (NSC) function. The molecular pathways limiting neuronal activity during aging remain largely unknown. In this work, we show that p38MAPK activity increases...
5.
Arrizabalaga O, Moreno-Cugnon L, Auzmendi-Iriarte J, Aldaz P, de Caceres I, Garros-Regulez L, et al.
Oncogenesis
. 2017 Dec;
6(12):401.
PMID: 29284798
The elucidation of mechanisms involved in resistance to therapies is essential to improve the survival of patients with malignant gliomas. A major feature possessed by glioma cells that may aid...
6.
Garros-Regulez L, Garcia I, Carrasco-Garcia E, Lantero A, Aldaz P, Moreno-Cugnon L, et al.
Front Oncol
. 2016 Nov;
6:222.
PMID: 27822457
Glioblastoma is the most common and malignant brain cancer in adults. Current therapy consisting of surgery followed by radiation and temozolomide has a moderate success rate and the tumor reappears....
7.
Garros-Regulez L, Aldaz P, Arrizabalaga O, Moncho-Amor V, Carrasco-Garcia E, Manterola L, et al.
Expert Opin Ther Targets
. 2016 Feb;
20(4):393-405.
PMID: 26878385
Background: SOX2 and SOX9 are commonly overexpressed in glioblastoma, and regulate the activity of glioma stem cells (GSCs). Their specific and overlapping roles in GSCs and glioma treatment remain unclear....
8.
Carrasco-Garcia E, Arrizabalaga O, Serrano M, Lovell-Badge R, Matheu A
Aging Cell
. 2015 May;
14(4):710-4.
PMID: 25990896
The impairment of the activity of the brain is a major feature of aging, which coincides with a decrease in the function of neural stem cells. We have previously shown...
9.
Carrasco-Garcia E, Sampron N, Aldaz P, Arrizabalaga O, Villanua J, Barrena C, et al.
Recent Pat Anticancer Drug Discov
. 2013 Apr;
8(3):216-27.
PMID: 23607282
Glioblastoma is the most common, aggressive and lethal brain tumor in adults. However, current therapeutic protocols have low success rates and average overall survival is less than 15 months. The...